IDEXX LABORATORIES REPORTS MATERIAL AGREEMENT

TL;DR

IDXX signed a big deal on 10/31, details TBD.

AI Summary

IDEXX LABORATORIES, INC. (IDXX) filed an 8-K on November 6, 2024, reporting the entry into a material definitive agreement as of October 31, 2024. The filing does not disclose specific details of the agreement, the counterparty, or any associated financial figures.

Why It Matters

This filing indicates a significant new contract or partnership for IDEXX Laboratories, which could impact its future business operations and financial performance.

Risk Assessment

Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and impact of the material definitive agreement.

Key Players & Entities

• IDEXX LABORATORIES INC /DE (company) — Registrant
• October 31, 2024 (date) — Date of earliest event reported
• November 6, 2024 (date) — Filing date
• Delaware (jurisdiction) — State of incorporation
• 000-19271 (document_id) — SEC File Number

FAQ

Key Financial Figures

• $0.10 — ange on which registered Common Stock, $0.10 par value per share IDXX NASDAQ Global

Filing Documents

• idxx-20241031.htm (8-K) — 28KB
• idxx-20241031_g1.jpg (GRAPHIC) — 47KB
• 0000874716-24-000142.txt ( ) — 285KB
• idxx-20241031.xsd (EX-101.SCH) — 2KB
• idxx-20241031_def.xml (EX-101.DEF) — 15KB
• idxx-20241031_lab.xml (EX-101.LAB) — 26KB
• idxx-20241031_pre.xml (EX-101.PRE) — 15KB
• idxx-20241031_htm.xml (XML) — 3KB

01. Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement. Effective as of October 31, 2024, IDEXX Laboratories, Inc. and certain of its affiliates entered into: (i) an Amendment No. 9 (the "U.S. Amendment") to the Agreement effective as of October 16, 2003 between IDEXX Operations, Inc. and Ortho-Clinical Diagnostics, Inc. ("Ortho"), as amended by Amendment Nos. 1 to 8 and the Letter Agreement dated July 28, 2023 (the "Original U.S. Supply Agreement" and as amended by the U.S. Amendment, the "U.S. Supply Agreement")) and (ii) an Amendment No. 7 (the "European Amendment") to the Agreement effective as of October 16, 2003 between IDEXX B.V. and Ortho, as amended by Amendment No. 1 to 6 and the Letter Agreement dated July 28, 2023 (the "Original European Supply Agreement" and as amended by the European Amendment, the "European Supply Agreement"). The U.S. Supply Agreement and European Supply Agreement provide for the supply by Ortho of dry slides for our veterinary chemistry analyzers, and the modifications made by the U.S. Amendment and European Amendment to the Original U.S. Supply Agreement and Original European Supply Agreement include, but are not limited to: An extension of the expiration dates of the Original U.S. Supply Agreement and Original European Supply Agreement to the end of 2044, and Modifications to the pricing arrangements, including volume tiers and associated pricing over the contract terms. The foregoing description is qualified in its entirety by reference to the Original U.S. Agreement and Original European Agreement, which are filed as Exhibits 10.1 to 10.21 to IDEXX's Annual Report on Form 10-K for the year ended December 31, 2023, and incorporated herein by reference, as amended by the U.S. Amendment and the European Amendment.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEXX LABORATORIES, INC. Date: November 6, 2024 By: /s/ Sharon E. Underberg Sharon E. Underberg Executive Vice President, General Counsel and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR